Eli Lilly Shares Outstanding 2010-2022 | LLY

Eli Lilly shares outstanding history from 2010 to 2022. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Eli Lilly shares outstanding for the quarter ending March 31, 2022 were 0.906B, a 0.66% decline year-over-year.
  • Eli Lilly 2021 shares outstanding were 0.912B, a 0.09% decline from 2020.
  • Eli Lilly 2020 shares outstanding were 0.913B, a 2.48% decline from 2019.
  • Eli Lilly 2019 shares outstanding were 0.936B, a 9.48% decline from 2018.
Eli Lilly Annual Shares Outstanding
(Millions of Shares)
2021 912
2020 913
2019 936
2018 1,034
2017 1,052
2016 1,062
2015 1,066
2014 1,074
2013 1,085
2012 1,117
2011 1,114
2010 1,106
2009 1,098
Eli Lilly Quarterly Shares Outstanding
(Millions of Shares)
2022-03-31 906
2021-12-31 912
2021-09-30 911
2021-06-30 910
2021-03-31 912
2020-12-31 913
2020-09-30 911
2020-06-30 911
2020-03-31 912
2019-12-31 936
2019-09-30 919
2019-06-30 925
2019-03-31 984
2018-12-31 1,034
2018-09-30 1,026
2018-06-30 1,030
2018-03-31 1,050
2017-12-31 1,052
2017-09-30 1,056
2017-06-30 1,057
2017-03-31 1,056
2016-12-31 1,062
2016-09-30 1,061
2016-06-30 1,060
2016-03-31 1,063
2015-12-31 1,066
2015-09-30 1,065
2015-06-30 1,066
2015-03-31 1,067
2014-12-31 1,074
2014-09-30 1,074
2014-06-30 1,076
2014-03-31 1,076
2013-12-31 1,085
2013-09-30 1,084
2013-06-30 1,084
2013-03-31 1,092
2012-12-31 1,117
2012-09-30 1,120
2012-06-30 1,119
2012-03-31 1,110
2011-12-31 1,114
2011-09-30 1,114
2011-06-30 1,114
2011-03-31 1,112
2010-12-31 1,106
2010-09-30 1,105
2010-06-30 1,104
2010-03-31 1,103
2009-12-31 1,098
2009-09-30 1,098
2009-06-30 1,097
2009-03-31 1,097
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $297.134B $28.318B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $472.758B 18.18
Pfizer (PFE) United States $281.050B 9.80
AbbVie (ABBV) United States $264.095B 11.58
Merck (MRK) United States $232.650B 13.14
Novartis AG (NVS) Switzerland $181.123B 13.18
GlaxoSmithKline (GSK) United Kingdom $108.662B 12.69
Novo Nordisk (NVO) Denmark $0.000B 32.27